EKSO - エクソ・バイオニック・ホ―ルディングズ （Ekso Bionics Holdings Inc.） エクソ・バイオニック・ホ―ルディングズEKSOのチャート
EKSOの企業情報
| symbol | EKSO |
|---|---|
| 会社名 | Ekso Bionics Holdings Inc （エクソ・バイオニック・ホ―ルディングズ） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Industrial Machinery/Components |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 エッソ･バイオニクス･ホールディングス（Ekso Bionics Holdings Inc.）（旧名：PN Med Group Inc.）医療、産業、軍事および消費者市場に向けの外骨格を設計、開発、販売を行う。同社はエンジニアリングサービスと医療、2つのセグメントで事業を行う。エンジニアリングサービスセグメントは外骨格におけるロボット工学の知識を通じてナショナル・サイエンス・ファウンデーションと国防総省先進研究プロジェクト機関などの団体からの契約や助成金を調達する共同研究開発サービス契約、技術ライセンス契約、政府補助金に従事する。医療セグメントは医学、軍事市場に応用する外骨格の設計、エンジニアリングおよび製造を行う。同社の外骨格システムは身体障害と身体の不自由なユーザーによっても使用できる。 エクソ・バイオニック・ホ―ルディングズは米国の医療器具メ―カ―。歩行を可能にするウエアラブルなエクソスケルトン(パワ―ドス―ツ)の開発・製造・販売に従事する。医療面では脊髄損傷や脳卒中などで歩行が困難になった患者に対し歩行を可能にするほか、軍事面では兵士が重い器具を長時間運搬する際の介助となる。本社はカリフォルニア州リッチモンド。 Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications. Founded in 2005, Ekso Bionics continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. Ekso Bionics is headquartered in the San Francisco Bay Area. |
| 本社所在地 | 1414 Harbour Way South Suite 1201 Richmond CA 94804 USA |
| 代表者氏名 | Steven A. Sherman スティーブンA.シャーマン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 510-984-1761 |
| 設立年月日 | 40909 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 92人 |
| url | www.eksobionics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ekso |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -29.07700 |
| 終値（lastsale） | 2.15 |
| 時価総額（marketcap） | 130789543.9 |
| 時価総額 | 時価総額（百万ドル） 125.92300 |
| 売上高 | 売上高（百万ドル） 9.53500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 118.11200 |
| 当期純利益 | 当期純利益（百万ドル） -31.19200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Ekso Bionics Holdings Inc revenues increased 66% to $5.5M. Net loss increased 15% to $15.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Gain (loss) on warrant liabilities decrease of 83% to $519K (income) Change in fair value contingent conside decrease of 91% to $16K (income). |
EKSOのテクニカル分析
EKSOのニュース
Ekso Bionics Holdings, Inc. (EKSO) Q3 2022 Earnings Call Transcript 2022/11/06 16:25:37 Seeking Alpha
Ekso Bionics Holdings, Inc. (NASDAQ:NASDAQ:EKSO) Q3 2022 Earnings Conference Call November 3, 2022 16:30 ET Company Participants Matt Steinberg - Investor Relations Steven Sherman -…
Ekso Bionics Reports Third Quarter 2022 Results 2022/11/03 20:05:00 GlobeNewswire
Quarterly Record of 33 EksoNR Bookings in Q3 2022
Preview: Ekso Bionics Holdings''s Earnings 2022/11/02 16:15:12 Benzinga
Ekso Bionics Holdings (NASDAQ: EKSO ) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here''s what investors need to know before the announcement. Analysts estimate that Ekso Bionics Holdings will report an earnings per share (EPS) of $-0.24. Ekso Bionics Holdings bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted … Full story available on Benzinga.com
Ekso Bionics to Report Third Quarter 2022 Financial Results on November 3, 2022 2022/10/27 12:00:00 GlobeNewswire
SAN RAFAEL, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2022 after the close of trading on Thursday, November 3, 2022. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.
Ekso Bionics to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022/09/06 20:05:00 GlobeNewswire
SAN RAFAEL, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, President and Chief Operating Officer, will be presenting virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.
Ekso Bionics to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022/09/06 20:05:00 GlobeNewswire
SAN RAFAEL, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, President and Chief Operating Officer, will be presenting virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.
Ekso Bionics Stock: Fragile Opportunity (NASDAQ:EKSO) 2022/08/24 08:34:59 Seeking Alpha
Ekso Bionics has added a new use case for the EksoNR exoskeleton, multiple sclerosis, opening some new avenues for marginal revenue growth.
Ekso Bionics Holdings''s Return On Capital Employed Insights 2022/08/05 14:38:45 Benzinga
According to Benzinga Pro data, during Q2, Ekso Bionics Holdings (NASDAQ: EKSO ) posted sales of $3.46 million. Earnings were up 35.54%, but Ekso Bionics Holdings still reported an overall loss of $2.98 million. Ekso Bionics Holdings collected $2.57 million in revenue during Q1, but reported earnings showed a $4.62 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company … Full story available on Benzinga.com
Ekso Bionics Holdings, Inc. (EKSO) CEO Steven Sherman on Q2 2022 Results - Earnings Call Transcript 2022/07/28 23:53:13 Seeking Alpha
Ekso Bionics Holdings, Inc. (NASDAQ:NASDAQ:EKSO) Q2 2022 Results Conference Call July 28, 2022 04:30 PM ET Company Participants David Carey - Head, Investor Relations Steven Sherman -…
Ekso Bionics Holdings GAAP EPS of -$0.23 beats by $0.01, revenue of $3.5M beats by $0.01M (NASDAQ:EKSO) 2022/07/28 20:22:00 Seeking Alpha
Ekso Bionics Holdings press release (EKSO): Q2 GAAP EPS of -$0.23 beats by $0.01.Revenue of $3.5M (+59.1% Y/Y) beats by $0.01M.Booked a total of 17 EksoNR units in the second quarter…
93 Biggest Movers From Yesterday 2022/06/14 07:58:38 Benzinga
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%. G Medical Innovations Holdings Ltd (NASDAQ: GMVD ) jumped 88.3% to close at $0.6499 after dropping more than 28% on Friday. Hillstream BioPharma, Inc. (NASDAQ: HILS ) gained 68.8% to close at $1.35 after it authorized a share repurchase program to acquire up to $1 million in common stock. OptiNose, Inc. (NASDAQ: OPTN ) jumped 41.1% to close at $2.61 after reporting top-line results of ReOpen2, its second Phase 3 clinical trial of XHANCE for the treatment of chronic sinusitis. AeroClean Technologies, Inc. (NASDAQ: AERC ) jumped 38% to settle at $17.25. Cyngn Inc. (NASDAQ: CYN ) gained 34.4% to close at $1.64. Cyngn recently announced its collaboration with Qualcomm to demonstrate autonomous mobile robots powered by the Qualcomm Robotics RB5 Platform at the Hannover Messe Expo.
BTCM, ANTE and CLNN among mid-day movers 2022/06/13 16:43:02 Seeking Alpha
Gainers: Day One Biopharmaceuticals DAWN +103%.Redbox Entertainment RDBXW +85%.OptiNose OPTN +37%.Cerberus Cyber Sentinel Corporation CISO +36%.Ekso Bionics Holdings…
Day One Biopharmaceuticals leads healthcare gainers; ContraFect, SciSparc among losers 2022/06/13 14:05:24 Seeking Alpha
Gainers: Day One Biopharmaceuticals (DAWN) +111%. Ekso Bionics Holdings (EKSO) +22%. OptiNose (OPTN) +19%. Tivic Health Systems (TIVC) +10%